Department of Clinical Laboratory, The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
Department of Internal Medicine, The People's Hospital of Guandu District, Kunming 650200, China.
Int J Med Sci. 2021 Jan 21;18(6):1348-1355. doi: 10.7150/ijms.52181. eCollection 2021.
The high-mobility group box protein 1 (HMGB1) rs1045411 polymorphism has been demonstrated to be associated with cancer risk in some studies. However, the results regarding this topic are inconsistent. A meta-analysis was applied to elucidate the association between the HMGB1 rs1045411 polymorphism and cancer risk. Ten relevant studies were subjected to our analysis, and pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. In total, of 3,918 cases and 5,296 controls were included in this study. The pooled ORs were calculated using a random-effects or fixed-effects model according to the heterogeneity. The pooled results revealed that TT genotype was significantly related to increased cancer risk in the comparisons of TT CC+TC (OR=1.35; 95% CI: 1.09-1.67; =0.005). Though no statistical significance was achieved between HMGB1 rs1045411 polymorphism and cancer risk in other four genetic models (T C: OR=1.08, 95% CI 0.90-1.30; TC CC: OR=1.01, 95% CI 0.82-1.24; CC TC+TT: OR=0.95, 95% CI 0.77-1.18; TT CC: OR=1.42; 95% CI 0.98-2.05), a trend of increased risk could be drawn. In the subgroup analysis by type of malignancy and ethnicity, no obvious difference was found in the tumour risk regarding the HMGB1 rs1045411 polymorphism amongst the cancer types except for breast cancer (OR=1.94; 95% CI: 1.05-3.59; =0.03) and hepatocellular carcinoma (OR=1.82; 95% CI: 1.15-2.88; =0.01), while rs1045411 polymorphism was positively associated with risks of cancer amongst Hans (OR=1.37; 95% CI: 1.11-1.69; =0.004) rather than Caucasians (OR=0.89; 95% CI: 0.26-3.02; =0.01). These results suggest that the HMGB1 rs1045411 polymorphism might be associated with increased cancer risk.
高迁移率族蛋白 B1（HMGB1）rs1045411 多态性已被证明与某些研究中的癌症风险相关。然而，关于这个主题的结果并不一致。我们进行了荟萃分析以阐明 HMGB1 rs1045411 多态性与癌症风险之间的关联。我们对 10 项相关研究进行了分析，并计算了合并的优势比（OR）和 95％置信区间（CI）。这项研究共纳入了 3918 例病例和 5296 例对照。根据异质性，使用随机效应或固定效应模型计算合并 OR。合并结果表明，在 TT 基因型与 CC+TC 基因型（OR=1.35；95％CI：1.09-1.67；=0.005）的比较中，TT 基因型与癌症风险增加显著相关。尽管在其他四种遗传模型（T C：OR=1.08，95％CI 0.90-1.30；TC CC：OR=1.01，95％CI 0.82-1.24；CC TC+TT：OR=0.95，95％CI 0.77-1.18；TT CC：OR=1.42；95％CI 0.98-2.05）中，HMGB1 rs1045411 多态性与癌症风险之间没有统计学意义，但可以看出风险增加的趋势。在按恶性肿瘤类型和种族进行的亚组分析中，除了乳腺癌（OR=1.94；95％CI：1.05-3.59；=0.03）和肝细胞癌（OR=1.82；95％CI：1.15-2.88；=0.01）外，HMGB1 rs1045411 多态性与其他癌症类型的肿瘤风险之间没有明显差异，而 rs1045411 多态性与汉族（OR=1.37；95％CI：1.11-1.69；=0.004）而不是白种人（OR=0.89；95％CI：0.26-3.02；=0.01）的癌症风险增加相关。这些结果表明，HMGB1 rs1045411 多态性可能与癌症风险增加有关。
